Results 261 to 270 of about 203,049 (341)
ESC Heart Failure, EarlyView.Abstract Aims Hypertrophic cardiomyopathy (HCM) is an inherited cardiomyopathy often caused by pathogenic variants in MYBPC3 and MYH7, encoding myosin‐binding protein C3 and myosin heavy chain 7, respectively. These variants can cause increased actin–myosin crossbridge cycling, resulting in ventricular hypercontractility, but mice lacking Mybpc3 ...
Isabell Yan +10 more
wiley +1 more source
ESC Heart Failure, EarlyView.Temporary RVAD support following HM3 LVAD is associated with high morbidity and mortality. Temporary RVAD support occurs most frequently in INTERMACS 1 or 2 patients and those who require pre‐operative VA‐ECMO. In addition to higher post‐operative mortality, a significantly higher risk of both dialysis and stroke at 1 year post‐implant was observed in ...
Vinh Q. Chau +12 more
wiley +1 more source
ESC Heart Failure, EarlyView.The figure illustrates the study design and key findings related to right ventricular myocardial work (RVMW) in heart failure with reduced ejection fraction (HFrEF) patients with and without pulmonary hypertension (PH). Patients were stratified into two groups: those with PH (n = 53) and those without PH (n = 49), as determined by right heart ...
Paolo Manca +12 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai +4 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Donation after circulatory death (DCD) has emerged as a strategy to increase the donor pool for heart transplantation (HT). Left ventricular assist device (LVAD) patients represent a discrete and unique population. We sought to explore the early outcomes of DCD‐HT compared with donation after brain death (DBD) HT in LVAD patients. Methods
Aris Karatasakis +13 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung +8 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Background Cardiac resynchronization therapy (CRT) is a key intervention for patients with heart failure. The choice between a CRT with defibrillator therapy (CRT‐D) and a CRT with pacemaker (CRT‐P) is influenced by individual clinical characteristics.
Bert Vandenberk +14 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Aims In heart failure patients, altered myocardial electrical fields linked to oedema may impair left ventricular function. While short‐term use of implanted microcurrent generators (C‐MIC) has shown promise, long‐term effects remain unclear.
Dragana B. Kosevic +14 more
wiley +1 more source
Cost-Benefit Analysis of Extended Antifungal Prophylaxis in Ventricular Assist Devices
, 2000 Jonathan L Skinner +6 more
openalex +1 more source
Right Atrial Pressure/Pulmonary Capillary Wedge Pressure Ratio Predicts In-Hospital Mortality in Left Ventricular Assist Device Recipients. [PDF]
J Clin MedKeskin B +8 more
europepmc +1 more source